Related Experiment Video
Updated: Jun 13, 2026
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience,
Shafak Aluwini1, Peter van Rooij, Misha Hoogeman
1Department of Radiation Oncology, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands. s.aluwini@erasmusmc.nl
Purpose:
The CyberKnife (CK), a linear accelerator mounted on a robotic device, enables excellent dose conformation to the target and minimizes dose to surrounding normal tissue. It is a very suitable device for performing hypofractionated stereotactic body radiotherapy as monotherapy for low- to intermediate-risk prostate cancer patients. We report our early experience using this technique.
Materials And Methods:
Between June 2008 and June 2009, 10 patients underwent CK monotherapy as treatment for their prostate cancer (stage
Results:
Median age of the patients was 71 years (range, 66-76). Three patients had stage T2a and 7a T1c disease, one patient had GS of 7, and all others had GS of 6. Median follow-up was 5.1 months. Median initial PSA was 8.3 ng/mL (range, 1.3-13.6 ng/mL). Median planning target volume delineated on computed tomography after matching with the magnetic resonance imaging scan was 107 cc (range, 42-158 cc). The median V100 of the prostate was 95.8% (range, 94.8-97.2). The D95 of the prostate was 38.3 Gy (range, 38.1-38.8 Gy). The constraints for the bladder, rectum, and urethra were well met. The International Prostate Symptom Scores after 3 months were stable compared with the pretreatment scores. Urinary and bowel Radiation Therapy Oncology Group symptoms were mild and within the expected levels.
Conclusions:
This regimen of stereotactic CK monotherapy for low- to intermediate-risk prostate cancer with excellent dose coverage of the prostate was well tolerated. Data collection is ongoing for further assessment of toxicity and PSA response.
